Truvestments Capital’s AstraZeneca AZN Stock Holding History

Truvestments Capital’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$35.9K	Hold	182	–	–	0.01%	549
2025 Q4	$33.5K	Sell	182 -117	-39%	-$20.5K	0.01%	511
2025 Q3	$45.8K	Sell	299 -31	-9%	-$4.69K	0.01%	459
2025 Q2	$46.1K	Sell	330 -114	-26%	-$16K	0.01%	410
2025 Q1	$65.2K	Buy	444 +372	+517%	+$53.8K	0.01%	352
2024 Q4	$9.38K	Buy	72 +41	+132%	+$5.74K	﹤0.01%	618
2024 Q3	$4.83K	Buy	+31	New	+$5K	﹤0.01%	692
2024 Q2	–	Sell	-49	Closed	-$6.64K	–	264
2024 Q1	$6.64K	Hold	49	–	–	﹤0.01%	528
2023 Q4	$6.6K	Hold	49	–	–	﹤0.01%	560
2023 Q3	$6.64K	Hold	49	–	–	﹤0.01%	481
2023 Q2	$7.01K	Hold	49	–	–	﹤0.01%	490
2023 Q1	$6.8K	Buy	+49	New	+$6.59K	﹤0.01%	474
2021 Q2	–	Sell	-464	Closed	-$46K	–	626
2021 Q1	$46K	Buy	+464	New	+$46.6K	0.03%	292
2019 Q4	–	Sell	-372	Closed	-$33K	–	176
2019 Q3	$33K	Hold	372	–	–	0.02%	316
2019 Q2	$31K	Sell	372 -780	-68%	-$61.2K	0.02%	348
2019 Q1	$93K	Buy	+1,152	New	+$90.8K	0.07%	168
2018 Q3	$82K	Buy	+1,038	New	+$78.5K	0.04%	287

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Truvestments Capital's AZN Position: Q1 2026 in Review

Truvestments Capital held its AstraZeneca (AZN) position steady in Q1 2026 at 182 shares worth $35.9K. The position accounts for 0.01% of the portfolio, ranked #549.

Truvestments Capital first reported a position in AZN in Q3 2018 and has held it in 17 quarters since. The position peaked at $93K in Q1 2019. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Truvestments Capital held 182 shares of AstraZeneca worth $35.9K as of Q1 2026.
Truvestments Capital left its AstraZeneca share count unchanged in Q1 2026.
AstraZeneca made up 0.01% of Truvestments Capital's portfolio in Q1 2026, its #549 holding.
Truvestments Capital first reported a position in AstraZeneca in Q3 2018 and has held it in 17 quarters since.
Truvestments Capital's AstraZeneca position peaked at $93K in Q1 2019.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Truvestments Capital's 13F filing for Q1 2026, filed 13 May 2026.